<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>107(5)</volume><submitter>Savendahl L</submitter><funding>Novo Nordisk</funding><pubmed_abstract>&lt;h4>Context&lt;/h4>Current GH therapy requires daily injections, which can be burdensome. Somapacitan is a long-acting GH derivative in development for treatment of GH deficiency (GHD).&lt;h4>Objective&lt;/h4>Evaluate the efficacy, safety, and tolerability of once-weekly somapacitan after 3 years of treatment.&lt;h4>Design&lt;/h4>A multicenter, randomized, controlled, phase 2 study comparing somapacitan and once-daily GH for 156 weeks (NCT02616562).&lt;h4>Setting&lt;/h4>Twenty-nine sites in 11 countries.&lt;h4>Patients&lt;/h4>Fifty-nine children with GHD randomized (1:1:1:1) and exposed to treatment. Fifty-three children completed the 3-year period.&lt;h4>Interventions&lt;/h4>Patients received somapacitan (0.04 [n = 14], 0.08 [n = 15], or 0.16 [n = 14] mg/kg/wk) or daily GH (n = 14) (0.034 mg/kg/d, equivalent to 0.238 mg/</pubmed_abstract><journal>The Journal of clinical endocrinology and metabolism</journal><pagination>1357-1367</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9016428</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3.</pubmed_title><pmcid>PMC9016428</pmcid><pubmed_authors>Battelino T</pubmed_authors><pubmed_authors>Brod M</pubmed_authors><pubmed_authors>Saenger P</pubmed_authors><pubmed_authors>Savendahl L</pubmed_authors><pubmed_authors>Hojby Rasmussen M</pubmed_authors><pubmed_authors>Horikawa R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3.</name><description>&lt;h4>Context&lt;/h4>Current GH therapy requires daily injections, which can be burdensome. Somapacitan is a long-acting GH derivative in development for treatment of GH deficiency (GHD).&lt;h4>Objective&lt;/h4>Evaluate the efficacy, safety, and tolerability of once-weekly somapacitan after 3 years of treatment.&lt;h4>Design&lt;/h4>A multicenter, randomized, controlled, phase 2 study comparing somapacitan and once-daily GH for 156 weeks (NCT02616562).&lt;h4>Setting&lt;/h4>Twenty-nine sites in 11 countries.&lt;h4>Patients&lt;/h4>Fifty-nine children with GHD randomized (1:1:1:1) and exposed to treatment. Fifty-three children completed the 3-year period.&lt;h4>Interventions&lt;/h4>Patients received somapacitan (0.04 [n = 14], 0.08 [n = 15], or 0.16 [n = 14] mg/kg/wk) or daily GH (n = 14) (0.034 mg/kg/d, equivalent to 0.238 mg/</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2025-04-04T19:32:02.689Z</modification><creation>2025-02-19T02:58:03.413Z</creation></dates><accession>S-EPMC9016428</accession><cross_references><pubmed>34964458</pubmed><doi>10.1210/clinem/dgab928</doi></cross_references></HashMap>